



09/30/04

PTO/SB/30 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RCE \$
EKA

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/673,958
Filing Date	August 13, 2001
First Named Inventor	M. Nanba
Art Unit	1635
Examiner Name	B. Whiteman
Attorney Docket Number	2519 USOP

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
ii. Other _____

- b. Enclosed

- | | |
|---|--|
| i. <input checked="" type="checkbox"/> Amendment/Reply | iii. <input type="checkbox"/> Information Disclosure Statement (IDS) |
| ii. <input type="checkbox"/> Affidavit(s)/ Declaration(s) | iv. <input checked="" type="checkbox"/> Other Fee Transmittal, Return Postcard and Declaration |

2. **Miscellaneous**

as to the Deposit of a Microorganism,

- Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a Petition of Extension
a. period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) of Time
b. Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- The Director is hereby authorized to charge the following fees, or credit any overpayments, to
a. Deposit Account No. 500799. I have enclosed a duplicate copy of this sheet.

- | | |
|---|---|
| i. <input checked="" type="checkbox"/> RCE fee required under 37 CFR 1.17(e) | 10/01/2004 MAHMED1 00000023 500799 09673958 |
| ii. <input checked="" type="checkbox"/> Extension of time fee (37 CFR 1.136 and 1.17) | 01 FC:1801 770.00 DA |
| iii. <input type="checkbox"/> Other _____ | |
- b. Check in the amount of \$ _____ enclosed
- c. Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Signature	<u>Elaine M. Ramesh</u>	Date	9/29/04
Name (Print/Type)	Elaine M. Ramesh, Ph.D., JD	Registration No.	43,032

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Signature	
Name (Print/Type)	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mailing # 2V 504908985 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	09/673,958	Art Unit:	1635
Filed:	August 13, 2001	Examiner:	B. Whiteman
1 st Inventor:	M. Nanba	Allowed:	
For:	Human Derived Immortalized Liver Cell Line	Batch:	
Atty. Dkt. No.	2519 US0P	Paper No.:	

RESPONSE "C"

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In connection with the filing of a Request for Continued Examination in response to the Advisory Action mailed September 15, 2004, Applicants respectfully request reconsideration of the claims in view of the amendment and remarks set forth below. A Declaration as to the Deposit of a Microorganism, Petition for a One-Month Extension of Time and authorization to pay the \$110.00 37 CFR Sec. 1.17(a)(1) fee and the \$770.00 RCE fee accompany this response.

AMENDMENT